PCV20

ApprovedBiologic

Merck & Co.

PCV20 is one of 32 biologic programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Pneumococcal VaccinesActive, not recruiting

LymphomaApproved

Active, not recruiting

Pneumococcal VaccinesPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

PCV20

Merck & Co.

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

1 8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Immunogenicity

NCT07284654

Phase 3Active, not recruiting

Pneumococcal Vaccines

NCT07425392

Q4 2027

Post-ApprovalActive, not recruiting

Lymphoma

NCT06049134

Q2 2029

Phase 1Recruiting

Children

NCT07300267

Clinical

Trials by Indication[1]

Immunogenicity3 trials

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05425732·2,663 enrolled

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Recruiting·VVaxcyte, Inc.·Phase 3·NCT07284654·4,000 enrolled

Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant

Not yet recruiting·LLiteVax BV·Phase 1·NCT06986239·80 enrolled

Vaccine1 trial

Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years

Unknown status·MMedical University of Vienna·Phase 4·NCT05767606·256 enrolled

Lymphoma1 trial

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 4·NCT06049134·30 enrolled

Respiratory Syncytial Virus (RSV)1 trial

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Completed· GSK logo

GSK·Phase 3·NCT05879107·1,113 enrolled

Children1 trial

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07300267·210 enrolled

1 more indication

Pneumococcal Vaccines1 trial

A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination

Active, not recruiting·VVaxcyte, Inc.·Phase 3·NCT07425392·752 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for PCV20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCV20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCV20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Merck & Co.

PCV20

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q2 2029

Trials by Indication[1]

Immunogenicity3 trials

Vaccine1 trial

Lymphoma1 trial

Respiratory Syncytial Virus (RSV)1 trial

Children1 trial

Pneumococcal Vaccines1 trial

References

Drug Info

Quick Facts

Related News